These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31671200)

  • 21. Prevalence and Dose Dependency Analysis of Pentosan Polysulfate Sodium Maculopathy.
    Philip AM; Wannamaker KW; Miller DM
    Ophthalmic Epidemiol; 2023 Feb; 30(1):82-87. PubMed ID: 35081852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pentosan Polysulfate-Associated Macular Disease in Patients With Interstitial Cystitis.
    Lyons RJ; Ahmad S; Ansari S; Foote JE; Jain N
    Obstet Gynecol; 2020 May; 135(5):1091-1094. PubMed ID: 32282604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nationwide Usage of Pentosan Polysulfate and Practice Patterns of Pentosan Polysulfate Maculopathy Screening in South Korea.
    Kim J; Kwon HY; Kim JH; Ahn SJ
    Ophthalmol Retina; 2024 Mar; 8(3):246-253. PubMed ID: 37832716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening practices and risk assessment for maculopathy in pentosan polysulfate users across different exposure levels.
    Kwon HY; Kim J; Ahn SJ
    Sci Rep; 2024 May; 14(1):11270. PubMed ID: 38760453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium.
    Pearce WA; Chen R; Jain N
    Ophthalmology; 2018 Nov; 125(11):1793-1802. PubMed ID: 29801663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PENTOSAN POLYSULFATE SODIUM (ELMIRON) MACULOPATHY: A Genetic Perspective.
    Kalaw FGP; Ignacio JCI; Wu CY; Ferreyra H; Nudleman E; Baxter SL; Freeman WR; Borooah S
    Retina; 2023 Jul; 43(7):1174-1181. PubMed ID: 36996461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pentosan Polysulfate Maculopathy-We Need to Know More.
    Maguire MG
    JAMA Ophthalmol; 2023 Mar; 141(3):266-267. PubMed ID: 36729463
    [No Abstract]   [Full Text] [Related]  

  • 28. PENTOSAN POLYSULFATE SODIUM-INDUCED PIGMENTARY MACULOPATHY WITH NONLEAKING CYSTOID MACULAR EDEMA SUCCESSFULLY TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    De Larochellière E; Bourgault S
    Retin Cases Brief Rep; 2022 Jul; 16(4):482-485. PubMed ID: 32541441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Maculopathy Associated with Long-Term Pentosan Polysulfate Therapy.
    Vora RA; Patel AP; Melles R
    Ophthalmology; 2020 Jun; 127(6):835-836. PubMed ID: 32085877
    [No Abstract]   [Full Text] [Related]  

  • 30. Pentosan Polysulfate Maculopathy: Prevalence, Spectrum of Disease, and Choroidal Imaging Analysis Based on Prospective Screening.
    Wang D; Velaga SB; Grondin C; Au A; Nittala M; Chhablani J; Vupparaboina KK; Gunnemann F; Jung J; Kim JH; Ip M; Sadda S; Sarraf D
    Am J Ophthalmol; 2021 Jul; 227():125-138. PubMed ID: 33651989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-Year Outcomes After Variable Duration of Drug Cessation in Patients With Maculopathy Associated With Pentosan Polysulfate Use.
    Jung EH; Lindeke-Myers A; Jain N
    JAMA Ophthalmol; 2023 Mar; 141(3):260-266. PubMed ID: 36729449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maculopathy secondary to chronic use of pentosan polysulfate sodium in treatment of interstitial cystitis.
    Atanasoff TL; Schleis MN; Keller JA
    Clin Exp Optom; 2023 Sep; 106(7):803-805. PubMed ID: 36031934
    [No Abstract]   [Full Text] [Related]  

  • 33. Large Subfoveal Vitelliform Lesions in a Case of Pentosan Polysulfate Maculopathy.
    Wannamaker KW; Sisk RA
    Ophthalmology; 2020 Dec; 127(12):1641. PubMed ID: 33222775
    [No Abstract]   [Full Text] [Related]  

  • 34. Microperimetry Findings in Pentosan Polysulfate Maculopathy.
    Most J; Kalaw FGP; Walker E; Arias JD; Charng J; Baxter SL; Nudleman E; Ferreyra H; Freeman WR; Chen FK; Borooah S
    Ophthalmol Retina; 2023 Nov; 7(11):1022-1024. PubMed ID: 37619623
    [No Abstract]   [Full Text] [Related]  

  • 35. New Insights Into Pentosan Polysulfate Maculopathy.
    Abou-Jaoude MM; Davis AM; Fraser CE; Leys M; Hinkle D; Odom JV; Maldonado RS
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jan; 52(1):13-22. PubMed ID: 33471910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of Pentosan Polysulfate Sodium Maculopathy in a Prospective Cohort.
    Somisetty S; Santina A; Au A; Romero-Morales V; Bousquet E; Sarraf D
    Am J Ophthalmol; 2023 Nov; 255():57-67. PubMed ID: 37327961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NINE-YEAR PROGRESSION OF PENTOSAN MACULOPATHY WITH MULTIMODAL RETINAL IMAGING.
    Santina A; Fogel-Levin M; Abraham N; Sarraf D
    Retin Cases Brief Rep; 2023 Nov; 17(6):664-667. PubMed ID: 35344532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macular Findings of Patients on Pentosan Polysulfate Sodium.
    Blackorby BL; Banda H; Smith BT; Shah GK
    Mil Med; 2023 Mar; 188(3-4):e579-e583. PubMed ID: 34296258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression of Pentosan-Polysulfate Sodium-Associated Retinopathy: Intermediate Follow-Up.
    Leung EH; Levie-Sprick A; Sharma S; Lee GD; Cho H; Yee DC; Mukkamala K
    Ophthalmic Surg Lasers Imaging Retina; 2023 Jul; 54(7):388-394. PubMed ID: 37310751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium.
    Wein AJ
    J Urol; 2020 Feb; 203(2):259-260. PubMed ID: 31721679
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.